FORFARMERSNV financials
FORFARMERSNV
Country: NL Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
724500YEIHQKMHTXW058 ISIN: NL0011832811 Financial statements
(EUR, as reported — unscaled; 111 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €3.15B | €2.75B |
| Gross profit | €611.2M | €518.3M |
| Other income | €11.8M | €15.0M |
| Operating expenses | €535.3M | €477.9M |
| Employee benefits expense | €207.8M | €183.3M |
| Raw materials & consumables used | €2.54B | €2.23B |
| Operating profit (EBIT) | €87.7M | €55.4M |
| Net finance income / (cost) | -€19.5M | -€16.2M |
| Profit before tax | €68.7M | €42.4M |
| Income tax expense | €14.3M | €8.2M |
| Profit for the year | €54.4M | €34.2M |
| — attributable to owners | €49.9M | €31.4M |
| — attributable to NCI | €4.5M | €2.8M |
| Total comprehensive income | €52.7M | €32.5M |
| Per share | ||
| Basic EPS | €0.56 | €0.35 |
| Diluted EPS | €0.56 | €0.35 |
| Free cash flow / share | €1.00 | €0.44 |
| Cash flow statement | ||
| Cash generated from operations | €167.2M | €83.7M |
| Net cash from operating activities | €148.3M | €70.2M |
| Income taxes paid | €12.3M | €6.8M |
| Net cash from investing activities | -€35.0M | -€78.3M |
| Purchase of PP&E (capex) | €50.9M | €26.8M |
| Purchase of intangibles | €800.0K | €1.4M |
| Net cash from financing activities | -€30.3M | -€7.4M |
| Dividends paid | €23.8M | €14.8M |
| Proceeds from borrowings | €125.5M | €50.0M |
| Repayments of borrowings | €111.3M | €30.0M |
| Lease liability payments | €17.6M | €12.6M |
| Net change in cash | €83.0M | -€15.5M |
| Balance sheet | ||
| Total assets | €1.11B | €942.1M |
| Non-current assets | €557.7M | €492.1M |
| Property, plant & equipment | €427.8M | €328.2M |
| Intangible assets & goodwill | €114.0M | €119.2M |
| Current assets | €552.7M | €450.0M |
| Inventories | €149.4M | €117.4M |
| Trade & other receivables | €277.3M | €261.3M |
| Cash & equivalents | €109.7M | €50.7M |
| Total equity | €438.4M | €338.3M |
| — attributable to owners | €357.8M | €328.4M |
| Non-controlling interests | €80.6M | €9.9M |
| Non-current liabilities | €163.8M | €200.2M |
| Long-term borrowings | €69.2M | €120.8M |
| Current liabilities | €508.2M | €403.6M |
| Short-term borrowings | €100.3M | €11.5M |
| Trade & other payables | €388.8M | €357.6M |
| Deferred tax liabilities | €19.2M | €17.7M |
| Derived metrics | ||
| Free cash flow | €97.4M | €43.4M |
| Operating margin | 2.8% | 2.0% |
| Net margin | 1.7% | 1.2% |
| Return on equity | 12.4% | 10.1% |
| Cash conversion ratio | 2.73× | 2.05× |
| Capex coverage | 2.91× | 2.62× |
| Other reported items | ||
| Adjustments For Amortisation Expense | €12.7M | €12.6M |
| Adjustments For Decrease Increase In Trade and Other Receivables | €27.0M | €16.6M |
| Adjustments For Depreciation Expense | €50.8M | €38.4M |
| Adjustments For Finance Income Cost | -€19.5M | -€16.2M |
| Adjustments For Gains Losses On Change In Fair Value Less Costs To Sell Biological Assets | -€1.5M | €300.0K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Trade and Other Receivables | -€3.1M | €800.0K |
| Adjustments For Income Tax Expense | €14.3M | €8.2M |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | €400.0K | €300.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | €800.0K | -€17.7M |
| Adjustments For Sharebased Payments | €1.5M | €1.1M |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | €500.0K | €3.2M |
| Cash and Cash Equivalents If Different From Statement of Financial Position | €105.6M | €23.2M |
| Cash Flows From Used In Operations Before Changes In Working Capital | €143.0M | €98.5M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | -€100.0K | €74.2M |
| Comprehensive Income Attributable To Noncontrolling Interests | €4.5M | €2.8M |
| Comprehensive Income Attributable To Owners of Parent | €48.2M | €29.7M |
| Current Biological Assets | €11.5M | €9.7M |
| Current Provisions | €5.7M | €4.2M |
| Current Tax Assets Current | €4.8M | €1.5M |
| Current Tax Liabilities Current | €9.3M | €2.8M |
| Deferred Tax Assets | €4.9M | €9.1M |
| Depreciation Amortisation and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €63.5M | €51.0M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners | €26.6M | €17.8M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | €0.30 | €0.20 |
| Dividends Received From Investments Accounted For Using Equity Method Classified As Investing Activities | €0 | €6.8M |
| Dividends Recognised As Distributions To Owners Per Share | €0.20 | €0.15 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€600.0K | €200.0K |
| Equity and Liabilities | €1.11B | €942.1M |
| Gains Losses On Cash Flow Hedges Before Tax | €1.2M | €100.0K |
| Gains Losses On Exchange Differences On Translation Before Tax | -€4.0M | €4.8M |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Trade Receivables | -€3.1M | €800.0K |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | €400.0K | €0 |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | €500.0K | -€2.1M |
| Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss of Control | €72.4M | — |
| Increase Decrease Through Sharebased Payment Transactions | €700.0K | €500.0K |
| Increase Decrease Through Transactions With Owners | €47.4M | -€14.6M |
| Increase Decrease Through Transfers and Other Changes Equity | €0 | €0 |
| Interest Paid Classified As Operating Activities | €6.6M | €6.7M |
| Interest Received Classified As Investing Activities | €1.0M | €1.5M |
| Investment Accounted For Using Equity Method | €1.6M | €33.5M |
| Investment Property | €600.0K | €600.0K |
| Liabilities | €672.0M | €603.8M |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | €0 | €9.4M |
| Noncurrent Payables | €47.2M | €36.9M |
| Noncurrent Provisions | €12.2M | €3.6M |
| Noncurrent Provisions For Employee Benefits | €16.0M | €21.2M |
| Noncurrent Receivables | €8.0M | €1.5M |
| Noncurrent Recognised Assets Defined Benefit Plan | €800.0K | €0 |
| Other Comprehensive Income | -€1.7M | -€1.7M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €2.0M | -€8.7M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€3.2M | €4.9M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €1.5M | -€6.6M |
| Other Expense By Nature | €267.1M | €242.8M |
| Payments For Debt Issue Costs | €1.4M | €0 |
| Payments To Acquire Or Redeem Entitys Shares | €1.7M | €0 |
| Proceeds From Disposal of Noncurrent Assets Or Disposal Groups Classified As Held For Sale and Discontinued Operations | €13.3M | €0 |
| Purchase of Treasury Shares | €1.7M | €0 |
| Share of Other Comprehensive Income of Associates and Joint Ventures Accounted For Using Equity Method That Will Not Be Reclassified To Profit Or Loss Before Tax | €0 | €0 |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €500.0K | €3.2M |
Methodology
Every line item above is a fact tagged in FORFARMERSNV's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.